S3.

Cox regression analyses for PFS in uncommon mutation patients after first-line EGFR-TKIs treatment or chemotherapy

Variables	Univariate analysis				Multivariate analysis
	HR	95% CI	P		HR	95% CI	P
PFS, progression-free survival; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; HR, hazard ratio; 95% CI, 95% confidence interval; ADC, adenocarcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status.
Age: <60 vs. ≥60 years	0.945	0.553–1.163	0.835
Sex: female vs. male	1.548	0.887–2.702	0.124
Status: recurrence vs. initial IIIb/IV	1.628	0.729–3.637	0.235
Distant metastases: No vs. Yes	0.790	0.460–1.358	0.394
Smoking: never vs. current/former	1.603	0.926–2.775	0.092		1.497	0.854–2.626	0.159
Pathology: non-ADC vs. ADC	0.216	0.062–0.750	0.016		0.260	0.073–0.923	0.037
ECOG PS: 0–1 vs. 2–4	2.483	0.583–10.585	0.219
Therapy: chemotherapy vs. EGFR-TKIs	1.039	0.593–1.819	0.894